MDRNA announced this week that it has begun a research study with Pfizer focused on RNAi drug discovery.
Under the deal, MDRNA will formulate Pfizer's oligonucleotides in its proprietary di-alkylated amino acids, or DiLA2, delivery vehicles for in vivo evaluation by the drugs giant. MDRNA will also design and synthesize UsiRNAs, duplex RNAs containing at least one non-nucleotide monomer, against Pfizer-specified targets.
Additional terms were not disclosed.